Mucosal damage: a major risk factor for severe complications after cytotoxic therapy.
about
Identifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: An informative gene network analysis.Oral mucositis induced by anticancer treatments: physiopathology and treatments.Management of bleeding in the terminally ill patient.Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support.Survey of topical oral solutions for the treatment of chemo-induced oral mucositis.Phase I study of the tolerability and pharmacokinetics of palifermin in children undergoing allogeneic hematopoietic stem cell transplantation.Inflammatory markers in patients after hematopoietic stem cell transplantation.Comparison of efficacy of cryotherapy and chlorhexidine to oral nutrition transition time in chemotherapy-induced oral mucositis.Cytokine Kinetics in Febrile Neutropenic Children: Insights on the Usefulness as Sepsis Biomarkers, Influence of Filgrastim, and Behavior of the IL-23/IL-17 Pathway.Cytomegalovirus colitis in patients without inflammatory bowel disease: a single center study.Intestinal pseudo-obstruction caused by diltiazem in a neutropenic patient.Efficacy of palifermin on oral mucositis and acute GVHD after hematopoietic stem cell transplantation (HSCT) in hematology malignancy patients: a meta-analysis of trials.Protective effects of aqueous extract of Solanum nigrum Linn. leaves in rat models of oral mucositis
P2860
Q33874148-2758E2E2-0289-4416-8964-533364E031F3Q35166803-B9945382-A571-481A-B99B-165214C4C491Q36194564-E62ECAB8-EE24-4D6D-9D87-1BC7C898D662Q36359466-01749982-DC5D-4602-8D72-2E9EE5CAA42AQ36440613-40A42A5E-3C8F-4EAF-95B8-C64E34708E84Q36515670-46AF8143-26C7-4076-B5AF-E79A1658B944Q38096877-5B208E7F-880A-4F65-918C-6524A43EFA2EQ39806536-6C5CF1A0-D7E2-413A-AC4C-E8CE5834887BQ40044862-8F77CAFA-2080-4EDE-94BE-25DFD264BFA2Q40355862-F6ACC53E-ED83-4C6D-8C8C-D70946EEC27BQ46519361-CBDB2509-D66B-41CB-B42B-9329377FA17AQ49332936-4B3A04C7-2B95-4FF6-871A-9C622E181461Q59075516-2E3659D4-A271-4F17-8A72-0D0F411B9F53
P2860
Mucosal damage: a major risk factor for severe complications after cytotoxic therapy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Mucosal damage: a major risk factor for severe complications after cytotoxic therapy.
@ast
Mucosal damage: a major risk factor for severe complications after cytotoxic therapy.
@en
type
label
Mucosal damage: a major risk factor for severe complications after cytotoxic therapy.
@ast
Mucosal damage: a major risk factor for severe complications after cytotoxic therapy.
@en
prefLabel
Mucosal damage: a major risk factor for severe complications after cytotoxic therapy.
@ast
Mucosal damage: a major risk factor for severe complications after cytotoxic therapy.
@en
P1433
P1476
Mucosal damage: a major risk factor for severe complications after cytotoxic therapy.
@en
P2093
Anna Cariello
Douglas E Peterson
P356
10.1053/J.SEMINONCOL.2004.04.006
P433
P577
2004-06-01T00:00:00Z